Market Analysis and Price Projections for Drug NDC: 51407-0460
Introduction
The pharmaceutical industry is a complex and dynamic market, influenced by various factors including regulatory changes, market competition, and economic conditions. This analysis focuses on the market and price projections for the drug with the NDC code 51407-0460, which is associated with Golden State Medical Supply, Inc.
Drug Identification
The NDC code 51407-0460 is linked to a specific pharmaceutical product manufactured by Golden State Medical Supply, Inc. However, the exact drug name is not specified in the provided sources. For the purpose of this analysis, we will consider general trends and factors affecting the pharmaceutical market, particularly for generic drugs.
Market Trends in the Pharmaceutical Industry
Generic Drug Market
The generic drug market, where Golden State Medical Supply, Inc. operates, is characterized by several key trends:
- Price Erosion: The generic drug industry is expected to experience mid-single-digit percent annual price erosion. This is due to intense competition and the commoditized nature of generic drugs[3].
- Revenue Growth: Despite price erosion, the industry is anticipated to see modest revenue growth, driven by increased demand and market expansion[3].
Biosimilars and Specialty Drugs
While the NDC code in question pertains to a generic drug, it's important to note the broader market trends:
- Biosimilars: These are expected to see substantial revenue growth, although intense competition may limit profitability[3].
- Specialty Drugs: These drugs, often biologics, continue to drive significant revenue growth due to their high prices and increasing demand[4].
Price Increases and Negotiations
Historical Price Increases
Many prescription drugs, including those selected for Medicare Part D negotiations, have seen significant price increases over recent years. For example, between 2018 and 2023, list prices for some drugs increased by 20% to 55%[2].
Medicare Drug Price Negotiation Program
Starting in January 2026, the Medicare Drug Price Negotiation Program will implement negotiated prices for certain drugs, including some that have seen substantial price increases. These negotiations are expected to result in discounts ranging from 38% to 79% compared to list prices[2].
International Price Comparisons
U.S. vs. Global Prices
Prescription drug prices in the U.S. are significantly higher than in other parts of the world. By 2022, prices in the U.S. were 5.5 times those in the OECD (excluding the U.S.) and 7.7 times those in the rest of the world (excluding the U.S.)[4].
Regulatory and Litigation Risks
FDA Inspections and Price-Fixing Litigation
The generic drug industry faces potential risks from increased FDA inspections of foreign manufacturing facilities and ongoing price-fixing litigation. These factors can impact production costs, regulatory compliance, and ultimately, drug prices[3].
Specific Considerations for NDC 51407-0460
Manufacturer Overview
Golden State Medical Supply, Inc. is a labeler and manufacturer of various pharmaceutical products. Their portfolio includes a range of generic drugs, some of which have specific expiration dates or recall notices[1].
Market Position
Given the generic nature of the drug, it is likely subject to the same market forces as other generic drugs. This includes competition from other manufacturers, potential price erosion, and regulatory oversight.
Price Projections
Short-Term Projections
In the short term, the price of the drug associated with NDC 51407-0460 is likely to follow the broader trend of mid-single-digit percent annual price erosion. This is due to the competitive nature of the generic drug market and the ongoing pressure to reduce healthcare costs[3].
Long-Term Projections
In the long term, the price could be further influenced by regulatory changes, such as the Medicare Drug Price Negotiation Program, and international pricing comparisons. If the drug falls under the negotiation program or faces increased competition from biosimilars or other generics, it could see more significant price reductions[2].
Key Takeaways
- Price Erosion: Expect mid-single-digit percent annual price erosion in the generic drug market.
- Regulatory Impact: Medicare negotiations and FDA inspections could significantly impact drug prices.
- International Comparisons: U.S. drug prices are significantly higher than global averages, which could influence future pricing strategies.
- Market Competition: Increased competition from biosimilars and other generics will continue to shape the market.
FAQs
-
What is the NDC code 51407-0460 associated with?
- The NDC code 51407-0460 is associated with a pharmaceutical product manufactured by Golden State Medical Supply, Inc., though the exact drug name is not specified in the provided sources.
-
How are generic drug prices expected to change in 2024?
- Generic drug prices are expected to experience mid-single-digit percent annual price erosion due to competition and market pressures[3].
-
What impact will the Medicare Drug Price Negotiation Program have on drug prices?
- The program is expected to result in discounts ranging from 38% to 79% compared to list prices for selected drugs starting in January 2026[2].
-
Why are U.S. drug prices higher than global averages?
- U.S. drug prices are higher due to a combination of factors including higher list prices and a drug mix that skews towards more expensive compounds[4].
-
What are the potential risks for the generic drug industry in 2024?
- The industry faces risks from increased FDA inspections of foreign manufacturing facilities and ongoing price-fixing litigation[3].
Sources
- FindACode: Golden State Medical Supply, Inc. - List of Drugs - NDC Labeler.
- ASPE - HHS.gov: Medicare Drug Price Negotiation Program.
- S&P Global: Pharmaceutical Industry 2024 Credit Outlook Is Stable As Revenue Growth Mitigates Pressures.
- ASPE - HHS.gov: International Market Size and Prices.
